[Edaily Reporter Shin Ha-yeon ] △SK hynix(000660) - Q2 revenue forecast at 87.1 trillion won (up 292.0% YoY), operating profit at 67.6 trillion won (up 638.0% YoY) -With robust HBM demand driven by Big Tech, coupled with large-scale CAPEX, the company is expected to benefit from HBM △LigaChem Biosciences(141080) - Expectations for progress in clinical development by partners, entry of the company’s own pipeline into clinical trials, and technology exports -Plans to file approximately 10 IND applications from its new ADC drug pipeline by 2027 △Hanwha Ocean(042660) -Profitability in the merchant ship segment is expected to continue improving as low-priced orders are cleared and revenue from high-priced vessels is recognized in earnest - Expectations for expanded orders for specialty vessels, such as Canada’s CPSP and South Korea’s KDDX, as well as increased orders for offshore plants
ABLE C&C(078520)is establishing a subsidiary in the Netherlands to serve as the control tower for its European operations. Following the establishment of its UK subsidiary, the company is setting up a…
On the afternoon of the 18th, at the Vuori pop-up store in Seongsu-dong, Seongdong-gu, Seoul, a different scene unfolded as I passed through the first and second floors—where clothes were displayed—an…
As global Big Pharma companies embark on large-scale mergers and acquisitions (M&A) to overcome the patent cliff and growth limitations, there are increasing instances of Chinese biotech companies bei…
